What is PH-HFpEF?
Pulmonary Hypertension (PH) resulting from Heart Failure with preserved Ejection Fraction (HFpEF) is a debilitating, often fatal disease. It’s the most common form of pulmonary hypertension globally. Yet, there are currently no approved treatments for this neglected disease.
Tenax is here to change that. Read more about PH-HFpEF and the staggering unmet need we aim to address.
Our drug candidate is called TNX-103.
TNX-103 is an oral formulation of levosimendan, a drug authorized for use in 60 countries, in its intravenous form, for acute decompensated heart failure (ADHF).
Our development program is derisked due to differentiated clinical data and levosimendan’s well established safety profile.
Shaped by heart failure and lung disease experts
Our innovate drug development strategy is guided by clinical insights into pulmonary and cardiovascular disorders, and state of the art understanding of disease pathophysiology drawn from leading world experts.
